Evidence map›Paper›PMID 38615278›Full record

ReviewInflammopharmacology2024

Comparison of different sources of mesenchymal stem cells: focus on inflammatory bowel disease.

Lihao Shi, Leilei Chen, Xizhuang Gao, Xufan Sun, Guiyuan Jin, Yonghong Yang, Yiming Shao, Fengqin Zhu, Guangxi Zhou

Abstract readReviewComparative Study
PubMed Publisher
In one paragraph

Review in Inflammopharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. A Rare Case of Small Bowel Ulceration Induced by COVID-19.Journal of inflammation research · 2025
    Article
  11. Review
  12. Review
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Lihao ShiCheeloo College of Medicine, Shandong University, Jinan, 250012, China.
Leilei ChenCheeloo College of Medicine, Shandong University, Jinan, 250012, China.
Xizhuang GaoClinical Medical College of Jining Medical University, Jining Medical University, Jining, Shandong, 272000, People's Republic of China.
Xufan SunClinical Medical College of Jining Medical University, Jining Medical University, Jining, Shandong, 272000, People's Republic of China.
Guiyuan JinMedical Research Center, Affiliated Hospital of Jining Medical University, Jining Medical University, Jining, People's Republic of China.
Yonghong YangMedical Research Center, Affiliated Hospital of Jining Medical University, Jining Medical University, Jining, People's Republic of China.
Yiming ShaoDepartment of Burns and Plastic Surgery, Affiliated Hospital of Jining Medical University, Jining, China.
Fengqin ZhuDepartment of Gastroenterology, Affiliated Hospital of Jining Medical University, Jining Medical University, Jining, Shandong, 272000, People's Republic of China.
Guangxi ZhouCheeloo College of Medicine, Shandong University, Jinan, 250012, China. zgx_viola@126.com.ORCID http://orcid.org/0000-0002-7803-605X

Funding

Tai Shan Young Scholar Foundation of Shandong Province tsqn202103190
6 · The paper itself

Abstract

Inflammatory bowel disease (IBD) poses a significant challenge in modern medicine, with conventional treatments limited by efficacy and associated side effects, necessitating innovative therapeutic approaches. Mesenchymal stem cells (MSC) have emerged as promising candidates for IBD treatment due to their immunomodulatory properties and regenerative potential. This thesis aims to explore and compare various sources of MSC and evaluate their efficacy in treating IBD. This study comprehensively analyses MSC derived from multiple sources, including bone marrow, adipose tissue, umbilical cord, and other potential reservoirs. Core elements of this investigation include assessing differences in cell acquisition, immunomodulatory effects, and differentiation capabilities among these MSC sources, as well as comparing their clinical trial outcomes in IBD patients to their therapeutic efficacy in animal models. Through meticulous evaluation and comparative analysis, this thesis aims to elucidate disparities in the efficacy of different MSC sources for IBD treatment, thereby identifying the most promising therapeutic applications. The findings of this study are intended to advance our understanding of MSC biology and offer valuable insights for selecting the most effective MSC sources for personalized IBD therapy. Ultimately, this research endeavor will optimise therapeutic strategies for managing inflammatory bowel disease through the utilization of MSC.

Indexed as

Inflammatory Bowel DiseasesMesenchymal Stem CellsMesenchymal Stem Cell TransplantationAdipose TissueAnimalsCell DifferentiationHumansInflammatory bowel disease (IBD)Mesenchymal stem cells (MSC)Multiple sourcesTherapeutic approaches

Identifiers

PMID38615278

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.